TNF
Tumor necrosis factor
As of the edition of 20 October 2026, TNF (tumor necrosis factor, UniProt P01375) has 24 drugs tested at it and 25 companies on the list, 14 on route A and 6 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P01375
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 52
- Disease areas
- Skin and connective tissue; Bones, joints and muscles; Immune system; Digestive system; Eye; Infections; Heart and blood vessels; Blood and lymph
- Registered trials of its drugs
- 1,172
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 7 |
| Active | 1 |
| Went quiet | 10 |
| Stopped | 5 |
| Status not established | 1 |
| Total | 24 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Adalimumab | Marketed | Phase 4 | Ends 2028 |
| Infliximab | Marketed | Phase 4 | Ended 2018 |
| Etanercept | Marketed | Phase 4 | Ended 2010 |
| Certolizumab pegol | Marketed | Phase 4 | Ended 2020 |
| Golimumab | Marketed | Phase 4 | Ends 2032 |
| Certolizumab | Marketed | Phase 4 | none listed |
| Pegipanermin | Stopped | Phase 3 | none listed |
| Remtolumab | Went quiet | Phase 2 | none listed |
| MEDI7352 | Stopped | Phase 2 | none listed |
| Ozoralizumab | Marketed | Phase 3 | none listed |
| Tanfanercept | Stopped | Phase 3 | none listed |
| AZD9773 | Went quiet | Phase 2 | none listed |
12 of 24 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 14 |
| Route B | 6 |
| Engaged | 3 |
| Undetermined | 2 |
| Total on the list | 25 |
| Company | Route |
|---|---|
| Pfizer | Route B |
| HanAll BioPharma | Route A |
| AstraZeneca | Route A |
The other 22 companies at TNF
In the product25 companies in all; 22 are not named here, and no score is.
See the 25 companies at TNF, ranked, with the facts behind eachRequest access. Nothing is shown until you do.